<!DOCTYPE html>
<html lang="tr">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>MBL EÄŸitim ModÃ¼lÃ¼</title>
<link href="https://fonts.googleapis.com/css2?family=Syne:wght@400;600;700;800&family=JetBrains+Mono:wght@400;500&family=Newsreader:ital,wght@0,400;0,500;1,400&display=swap" rel="stylesheet">
<style>
  :root {
    --bg: #0a0d14;
    --bg2: #0f1420;
    --bg3: #151c2e;
    --bg4: #1a2238;
    --border: #1e2d4a;
    --accent: #00d4ff;
    --accent2: #ff6b35;
    --accent3: #7cf779;
    --accent4: #ffd166;
    --text: #e8edf5;
    --text2: #8899bb;
    --text3: #5a7090;
    --danger: #ff4466;
    --success: #3dffa0;
    --font-head: 'Syne', sans-serif;
    --font-body: 'Newsreader', serif;
    --font-mono: 'JetBrains Mono', monospace;
  }
  * { margin:0; padding:0; box-sizing:border-box; }
  body { background:var(--bg); color:var(--text); font-family:var(--font-body); font-size:16px; line-height:1.7; min-height:100vh; }
  
  /* LOGIN */
  #loginScreen { display:flex; align-items:center; justify-content:center; min-height:100vh; background:radial-gradient(ellipse at 30% 40%, #001833 0%, var(--bg) 70%); }
  .loginBox { background:var(--bg2); border:1px solid var(--border); border-radius:16px; padding:48px 40px; width:360px; text-align:center; }
  .loginBox .logo { font-family:var(--font-head); font-size:13px; letter-spacing:4px; color:var(--accent); text-transform:uppercase; margin-bottom:8px; }
  .loginBox h1 { font-family:var(--font-head); font-size:24px; font-weight:800; color:var(--text); margin-bottom:4px; }
  .loginBox p { color:var(--text2); font-size:13px; margin-bottom:32px; }
  .loginBox input { width:100%; background:var(--bg3); border:1px solid var(--border); border-radius:8px; padding:12px 16px; color:var(--text); font-family:var(--font-body); font-size:15px; outline:none; transition:.2s; }
  .loginBox input:focus { border-color:var(--accent); }
  .loginBox button { width:100%; margin-top:12px; background:var(--accent); color:#000; border:none; border-radius:8px; padding:13px; font-family:var(--font-head); font-size:15px; font-weight:700; cursor:pointer; transition:.2s; }
  .loginBox button:hover { background:#33ddff; }
  .loginBox .err { color:var(--danger); font-size:13px; margin-top:8px; }

  /* LAYOUT */
  #app { display:none; }
  .sidebar { position:fixed; left:0; top:0; bottom:0; width:260px; background:var(--bg2); border-right:1px solid var(--border); overflow-y:auto; z-index:100; display:flex; flex-direction:column; }
  .sidebar-header { padding:24px 20px 16px; border-bottom:1px solid var(--border); }
  .sidebar-header .tag { font-family:var(--font-mono); font-size:10px; color:var(--accent); letter-spacing:3px; text-transform:uppercase; margin-bottom:6px; }
  .sidebar-header h2 { font-family:var(--font-head); font-size:16px; font-weight:800; line-height:1.3; }
  .sidebar nav { flex:1; padding:12px 0; }
  .nav-item { display:flex; align-items:center; gap:10px; padding:9px 20px; cursor:pointer; font-family:var(--font-head); font-size:13px; font-weight:600; color:var(--text2); transition:.15s; border-left:2px solid transparent; }
  .nav-item:hover { color:var(--text); background:var(--bg3); }
  .nav-item.active { color:var(--accent); border-left-color:var(--accent); background:rgba(0,212,255,.06); }
  .nav-item .num { font-family:var(--font-mono); font-size:11px; color:var(--text3); min-width:20px; }
  .sidebar-footer { padding:16px 20px; border-top:1px solid var(--border); }
  .user-badge { display:flex; align-items:center; gap:10px; }
  .avatar { width:32px; height:32px; background:linear-gradient(135deg, var(--accent), var(--accent2)); border-radius:50%; display:flex; align-items:center; justify-content:center; font-family:var(--font-head); font-size:12px; font-weight:700; color:#000; flex-shrink:0; }
  .user-info { flex:1; min-width:0; }
  .user-name { font-family:var(--font-head); font-size:13px; font-weight:700; color:var(--text); white-space:nowrap; overflow:hidden; text-overflow:ellipsis; }
  .user-sub { font-size:11px; color:var(--text3); }
  .logout-btn { background:rgba(255,68,102,.12); border:1px solid rgba(255,68,102,.3); color:var(--danger); cursor:pointer; font-size:11px; font-family:var(--font-head); font-weight:700; padding:5px 11px; border-radius:6px; transition:.2s; letter-spacing:.5px; white-space:nowrap; }
  .logout-btn:hover { background:rgba(255,68,102,.28); border-color:var(--danger); transform:scale(1.04); }
  .sidebar-footer { padding:14px 20px; border-top:1px solid var(--border); background:var(--bg2); }
  
  /* MAIN */
  .main { margin-left:260px; padding:40px 48px; max-width:980px; }
  .section { display:none; }
  .section.active { display:block; }
  
  /* TYPOGRAPHY */
  .page-tag { font-family:var(--font-mono); font-size:11px; color:var(--accent); letter-spacing:3px; text-transform:uppercase; margin-bottom:10px; }
  h1.page-title { font-family:var(--font-head); font-size:36px; font-weight:800; line-height:1.15; margin-bottom:8px; }
  h1.page-title span { color:var(--accent); }
  .page-sub { color:var(--text2); font-size:16px; margin-bottom:36px; max-width:660px; }
  h2.sec-head { font-family:var(--font-head); font-size:22px; font-weight:700; color:var(--text); margin:36px 0 14px; display:flex; align-items:center; gap:10px; }
  h2.sec-head::before { content:''; display:block; width:3px; height:22px; background:var(--accent); border-radius:2px; }
  h3.sub-head { font-family:var(--font-head); font-size:16px; font-weight:700; color:var(--accent4); margin:24px 0 10px; }
  p { margin-bottom:14px; font-size:16px; line-height:1.8; }
  
  /* CITE */
  .cite { font-family:var(--font-mono); font-size:10px; vertical-align:super; color:var(--accent); cursor:default; }
  
  /* CARDS */
  .card { background:var(--bg2); border:1px solid var(--border); border-radius:12px; padding:20px 24px; margin-bottom:16px; }
  .card-grid { display:grid; grid-template-columns:1fr 1fr; gap:16px; margin-bottom:20px; }
  .card.highlight { border-color:var(--accent); background:rgba(0,212,255,.04); }
  .card.warn { border-color:var(--accent2); background:rgba(255,107,53,.04); }
  .card.success { border-color:var(--accent3); background:rgba(124,247,121,.04); }
  .card.gold { border-color:var(--accent4); background:rgba(255,209,102,.04); }
  
  /* FORMULA BOX */
  .formula { background:var(--bg3); border:1px solid var(--border); border-radius:8px; padding:16px 20px; font-family:var(--font-mono); font-size:14px; color:var(--accent); margin:16px 0; text-align:center; letter-spacing:.5px; }
  .formula .big { font-size:20px; font-weight:500; }
  
  /* TABLE */
  table { width:100%; border-collapse:collapse; margin:16px 0 24px; font-size:14px; }
  th { background:var(--bg3); color:var(--accent); font-family:var(--font-head); font-size:12px; letter-spacing:1px; text-transform:uppercase; padding:10px 14px; text-align:left; border-bottom:1px solid var(--border); }
  td { padding:10px 14px; border-bottom:1px solid var(--border); color:var(--text2); vertical-align:top; }
  tr:last-child td { border-bottom:none; }
  tr:hover td { background:rgba(255,255,255,.02); }
  td.good { color:var(--success); font-family:var(--font-mono); font-size:13px; }
  td.bad { color:var(--danger); font-family:var(--font-mono); font-size:13px; }
  td.neu { color:var(--accent4); font-family:var(--font-mono); font-size:13px; }
  
  /* FLOW CHART */
  .flow { display:flex; flex-direction:column; align-items:center; gap:0; margin:24px 0; }
  .flow-box { background:var(--bg3); border:1px solid var(--border); border-radius:10px; padding:12px 28px; text-align:center; font-family:var(--font-head); font-size:14px; font-weight:600; min-width:260px; position:relative; }
  .flow-box.start { border-color:var(--text3); color:var(--text2); font-size:13px; }
  .flow-box.decision { background:var(--bg4); border-color:var(--accent4); color:var(--accent4); }
  .flow-box.pos { border-color:var(--accent3); color:var(--accent3); background:rgba(124,247,121,.05); }
  .flow-box.neg { border-color:var(--text3); color:var(--text2); background:var(--bg); }
  .flow-box.mbl { border-color:var(--danger); color:var(--danger); background:rgba(255,68,102,.05); font-size:15px; }
  .flow-box.ser { border-color:var(--accent4); color:var(--accent4); background:rgba(255,209,102,.05); }
  .flow-arrow { width:2px; height:24px; background:var(--border); margin:0 auto; }
  .flow-branch { display:flex; gap:32px; align-items:flex-start; justify-content:center; width:100%; margin:0; }
  .flow-branch-col { display:flex; flex-direction:column; align-items:center; gap:0; }
  .flow-label { font-family:var(--font-mono); font-size:11px; color:var(--text3); text-align:center; padding:4px 0; }
  
  /* BADGE */
  .badge { display:inline-block; padding:2px 10px; border-radius:4px; font-family:var(--font-mono); font-size:11px; font-weight:500; letter-spacing:.5px; }
  .badge-green { background:rgba(61,255,160,.15); color:var(--success); }
  .badge-red { background:rgba(255,68,102,.15); color:var(--danger); }
  .badge-blue { background:rgba(0,212,255,.15); color:var(--accent); }
  .badge-orange { background:rgba(255,107,53,.15); color:var(--accent2); }
  .badge-gold { background:rgba(255,209,102,.15); color:var(--accent4); }
  
  /* TTS */
  .tts-bar { display:flex; align-items:center; gap:10px; background:var(--bg3); border:1px solid var(--border); border-radius:8px; padding:10px 16px; margin-bottom:24px; }
  .tts-btn { background:var(--accent); color:#000; border:none; border-radius:6px; padding:6px 14px; font-family:var(--font-head); font-size:12px; font-weight:700; cursor:pointer; transition:.2s; }
  .tts-btn:hover { background:#33ddff; }
  .tts-btn.stop { background:var(--accent2); }
  .tts-status { font-family:var(--font-mono); font-size:11px; color:var(--text3); flex:1; }
  
  /* QUIZ */
  .quiz-progress { background:var(--bg3); border-radius:100px; height:4px; margin-bottom:28px; overflow:hidden; }
  .quiz-progress-bar { height:100%; background:linear-gradient(90deg, var(--accent), var(--accent2)); border-radius:100px; transition:width .4s; }
  .quiz-q-num { font-family:var(--font-mono); font-size:12px; color:var(--text3); margin-bottom:8px; }
  .quiz-question { font-family:var(--font-head); font-size:20px; font-weight:700; line-height:1.4; margin-bottom:24px; }
  .quiz-options { display:flex; flex-direction:column; gap:10px; margin-bottom:24px; }
  .quiz-opt { background:var(--bg3); border:1px solid var(--border); border-radius:10px; padding:14px 18px; cursor:pointer; font-size:15px; transition:.2s; display:flex; align-items:center; gap:12px; }
  .quiz-opt:hover { border-color:var(--accent); background:rgba(0,212,255,.04); }
  .quiz-opt.selected { border-color:var(--accent); background:rgba(0,212,255,.08); }
  .quiz-opt.correct { border-color:var(--success); background:rgba(61,255,160,.08); }
  .quiz-opt.wrong { border-color:var(--danger); background:rgba(255,68,102,.08); }
  .quiz-opt .opt-key { font-family:var(--font-mono); font-size:12px; color:var(--text3); min-width:20px; }
  .quiz-explain { background:var(--bg3); border-left:3px solid var(--accent); border-radius:0 8px 8px 0; padding:12px 16px; font-size:14px; color:var(--text2); margin-bottom:16px; display:none; }
  .quiz-explain.show { display:block; }
  .quiz-nav { display:flex; gap:10px; }
  .quiz-btn { background:var(--bg3); border:1px solid var(--border); border-radius:8px; padding:10px 20px; font-family:var(--font-head); font-size:13px; font-weight:700; color:var(--text); cursor:pointer; transition:.2s; }
  .quiz-btn:hover { border-color:var(--accent); color:var(--accent); }
  .quiz-btn.primary { background:var(--accent); border-color:var(--accent); color:#000; }
  .quiz-btn.primary:hover { background:#33ddff; }
  .quiz-result { text-align:center; padding:40px 20px; }
  .quiz-result .score { font-family:var(--font-head); font-size:64px; font-weight:800; line-height:1; }
  .quiz-result .score-label { color:var(--text2); margin:8px 0 24px; font-size:15px; }
  .quiz-result .perf { font-family:var(--font-mono); font-size:14px; color:var(--accent); margin-bottom:32px; }
  
  /* HISTORY */
  .score-hist { background:var(--bg3); border-radius:8px; padding:12px 16px; margin-bottom:16px; }
  .score-hist h4 { font-family:var(--font-head); font-size:13px; color:var(--text2); margin-bottom:10px; letter-spacing:1px; text-transform:uppercase; }
  .hist-item { display:flex; justify-content:space-between; padding:6px 0; border-bottom:1px solid var(--border); font-size:13px; }
  .hist-item:last-child { border-bottom:none; }
  .hist-score { font-family:var(--font-mono); color:var(--accent); }
  
  /* REF */
  .ref-list { counter-reset:ref; }
  .ref-item { display:flex; gap:12px; padding:10px 0; border-bottom:1px solid var(--border); font-size:14px; color:var(--text2); }
  .ref-item:last-child { border-bottom:none; }
  .ref-num { font-family:var(--font-mono); font-size:12px; color:var(--accent); min-width:24px; }
  
  /* WELCOME */
  .welcome-grid { display:grid; grid-template-columns:repeat(3,1fr); gap:16px; margin:24px 0; }
  .welcome-card { background:var(--bg2); border:1px solid var(--border); border-radius:12px; padding:20px; cursor:pointer; transition:.2s; }
  .welcome-card:hover { border-color:var(--accent); transform:translateY(-2px); }
  .welcome-card .icon { font-size:28px; margin-bottom:10px; }
  .welcome-card h3 { font-family:var(--font-head); font-size:14px; font-weight:700; margin-bottom:4px; }
  .welcome-card p { font-size:12px; color:var(--text3); margin:0; line-height:1.5; }
  
  /* SCROLLBAR */
  ::-webkit-scrollbar { width:5px; }
  ::-webkit-scrollbar-track { background:var(--bg); }
  ::-webkit-scrollbar-thumb { background:var(--border); border-radius:3px; }
  
  /* SECTION NAV FOOTER */
  .section-nav-footer { margin-top:48px; padding-top:24px; border-top:1px solid var(--border); }
  .section-nav-footer .snf-label { font-family:var(--font-mono); font-size:10px; color:var(--text3); letter-spacing:3px; text-transform:uppercase; margin-bottom:14px; }
  .snf-grid { display:flex; flex-wrap:wrap; gap:8px; }
  .snf-chip { display:inline-flex; align-items:center; gap:6px; padding:7px 14px; background:var(--bg3); border:1px solid var(--border); border-radius:8px; font-family:var(--font-head); font-size:12px; font-weight:600; color:var(--text2); cursor:pointer; transition:.18s; }
  .snf-chip:hover { border-color:var(--accent); color:var(--accent); background:rgba(0,212,255,.06); }
  .snf-chip.current { border-color:var(--text3); color:var(--text3); cursor:default; pointer-events:none; }
  .snf-chip .snf-num { font-family:var(--font-mono); font-size:10px; color:var(--text3); }
  .snf-chip:hover .snf-num { color:var(--accent); }

  @media (max-width:768px) {
    .sidebar { width:100%; height:auto; position:relative; }
    .main { margin-left:0; padding:20px; }
    .card-grid { grid-template-columns:1fr; }
    .welcome-grid { grid-template-columns:1fr 1fr; }
  }
</style>
</head>
<body>

<!-- LOGIN -->
<div id="loginScreen">
  <div class="loginBox">
    <div class="logo">ğŸ”¬ Klinik Mikrobiyoloji</div>
    <h1>MBL EÄŸitim ModÃ¼lÃ¼</h1>
    <p>Metallo-Î²-Laktamazlar: TanÄ±, Tedavi & Tuzaklar</p>
    <input type="text" id="loginUser" placeholder="KullanÄ±cÄ± adÄ±" autocomplete="off">
    <input type="password" id="loginPass" placeholder="Åifre" style="margin-top:10px">
    <button id="loginBtn">GiriÅŸ Yap</button>
    <div class="err" id="loginErr"></div>
    <div style="color:var(--text3);font-size:11px;margin-top:16px">Demo: herhangi bir kullanÄ±cÄ± / 1234</div>
  </div>
</div>

<!-- APP -->
<div id="app">
  <div class="sidebar">
    <div class="sidebar-header">
      <div class="tag">ğŸ§¬ ModÃ¼l v2.0 â€” 2026</div>
      <h2>MBL Ãœreten Gram-Negatifler</h2>
    </div>
    <nav id="sideNav">
      <div class="nav-item active" data-sec="home"><span class="num">00</span>Genel BakÄ±ÅŸ</div>
      <div class="nav-item" data-sec="temel"><span class="num">01</span>MBL Nedir?</div>
      <div class="nav-item" data-sec="mcim"><span class="num">02</span>mCIM Testi</div>
      <div class="nav-item" data-sec="ecim"><span class="num">03</span>eCIM Testi</div>
      <div class="nav-item" data-sec="kombine"><span class="num">04</span>Kombine Disk</div>
      <div class="nav-item" data-sec="algoritma"><span class="num">05</span>TanÄ± AlgoritmasÄ±</div>
      <div class="nav-item" data-sec="mblvskpc"><span class="num">06</span>MBL vs KPC</div>
      <div class="nav-item" data-sec="tedavi"><span class="num">07</span>Tedavi</div>
      <div class="nav-item" data-sec="tuzaklar"><span class="num">08</span>Lab TuzaklarÄ±</div>
      <div class="nav-item" data-sec="molekuler"><span class="num">09</span>MolekÃ¼ler Panel</div>
      <div class="nav-item" data-sec="quiz"><span class="num">10</span>Quiz</div>
      <div class="nav-item" data-sec="refs"><span class="num">Ref</span>Kaynaklar</div>
    </nav>
    <div class="sidebar-footer">
      <div class="user-badge">
        <div class="avatar" id="avatarEl">U</div>
        <div class="user-info">
          <div class="user-name" id="userNameEl">KullanÄ±cÄ±</div>
          <div class="user-sub">EÄŸitim modÃ¼lÃ¼</div>
        </div>
        <button class="logout-btn" id="logoutBtn">â†© Ã‡Ä±kÄ±ÅŸ</button>
      </div>
    </div>
  </div>

  <div class="main">

    <!-- TTS BAR -->
    <div class="tts-bar">
      <button class="tts-btn" id="ttsPlay">â–¶ Sesli Oku</button>
      <button class="tts-btn stop" id="ttsStop">â–  Durdur</button>
      <span class="tts-status" id="ttsStatus">BÃ¶lÃ¼m metnini sesli dinleyebilirsiniz (EN/TR)</span>
    </div>

    <!-- 00 HOME -->
    <div class="section active" id="sec-home">
      <div class="page-tag">GiriÅŸ</div>
      <h1 class="page-title">Metallo-Î²-Laktamazlar<br><span>Dedektif HikÃ¢yesi</span></h1>
      <p class="page-sub">Laboratuvarda MBL aramak kÃ¼Ã§Ã¼k bir dedektiflik oyunu gibidir. Enzim gÃ¶rÃ¼nmez; yaptÄ±ÄŸÄ± iÅŸin izini sÃ¼rersiniz. Bu modÃ¼l size o izi nasÄ±l takip edeceÄŸinizi Ã¶ÄŸretir.</p>
      <div class="welcome-grid">
        <div class="welcome-card" data-goto="temel"><div class="icon">ğŸ§¬</div><h3>MBL Nedir?</h3><p>Ambler SÄ±nÄ±f B, Ã§inko baÄŸÄ±mlÄ± Î²-laktamazlar</p></div>
        <div class="welcome-card" data-goto="algoritma"><div class="icon">ğŸ”¬</div><h3>TanÄ± AlgoritmasÄ±</h3><p>AdÄ±m adÄ±m fenotipik doÄŸrulama akÄ±ÅŸÄ±</p></div>
        <div class="welcome-card" data-goto="tedavi"><div class="icon">ğŸ’Š</div><h3>Tedavi</h3><p>CZA+ATM, cefiderocol ve Ã¶tesi</p></div>
        <div class="welcome-card" data-goto="mblvskpc"><div class="icon">âš–ï¸</div><h3>MBL vs KPC</h3><p>Fenotipik ve inhibitÃ¶r profil farklarÄ±</p></div>
        <div class="welcome-card" data-goto="tuzaklar"><div class="icon">âš ï¸</div><h3>Lab TuzaklarÄ±</h3><p>En sÄ±k yanlÄ±ÅŸ yorumlar ve Ã§Ã¶zÃ¼mleri</p></div>
        <div class="welcome-card" data-goto="quiz"><div class="icon">ğŸ¯</div><h3>Quiz</h3><p>10 klinik soru ile bilginizi test edin</p></div>
      </div>
      <div class="card highlight">
        <h3 class="sub-head">Bu modÃ¼lÃ¼ kimler kullanmalÄ±?</h3>
        <p>Klinik mikrobiyoloji uzmanlarÄ±, enfeksiyon hastalÄ±klarÄ± hekimleri, asistan hekimler ve laboratuvar teknisyenleri. Ä°Ã§erik CLSI M100 (34. baskÄ±, 2024),<span class="cite">[4]</span> IDSA AMR KÄ±lavuzu 2024<span class="cite">[1]</span> ve ESCMID MDR-GNB Rehberi 2022<span class="cite">[2]</span> doÄŸrultusunda hazÄ±rlanmÄ±ÅŸtÄ±r.</p>
      </div>
    </div>

    <!-- 01 TEMEL -->
    <div class="section" id="sec-temel">
      <div class="page-tag">01 â€” Temel Bilgi</div>
      <h1 class="page-title">MBL <span>Nedir?</span></h1>
      <p class="page-sub">Metallo-Î²-laktamazlar, aktif bÃ¶lgelerinde Ã§inko iyonu kullanan enzimlerdir. Bu Ã¶zellik, onlarÄ± hem gÃ¼Ã§lÃ¼ hem de tespit edilebilir kÄ±lar.</p>
      
      <h2 class="sec-head">TanÄ±m & SÄ±nÄ±flandÄ±rma</h2>
      <p>MBL'ler, Ambler molekÃ¼ler sÄ±nÄ±flandÄ±rmasÄ±nda <strong>SÄ±nÄ±f B</strong> Î²-laktamazlara karÅŸÄ±lÄ±k gelir.<span class="cite">[3]</span> Fonksiyonel gruplandÄ±rmada (Bush-Jacoby) Grup 3'te yer alÄ±rlar. Temel Ã¶zellikleri ÅŸunlardÄ±r:</p>
      <div class="card-grid">
        <div class="card highlight">
          <h3 class="sub-head" style="color:var(--accent)">YapÄ±sal Ã–zellik</h3>
          <p>Aktif bÃ¶lgede <strong>1 veya 2 Ã§inko (ZnÂ²âº)</strong> iyonu bulunur. Bu metal iyonu katalitik aktivite iÃ§in zorunludur.<span class="cite">[3]</span> EDTA gibi ÅŸelat yapÄ±cÄ±lar ZnÂ²âº'yi baÄŸlayarak enzimi iÅŸlevsiz kÄ±lar â€” bu Ã¶zellik tÃ¼m fenotipik testlerin temelidir.</p>
        </div>
        <div class="card warn">
          <h3 class="sub-head" style="color:var(--accent2)">Klinik Ã–nemi</h3>
          <p>Karbapenem dahil neredeyse tÃ¼m Î²-laktamlarÄ± hidroliz ederler. Monobaktamlar (aztreonam) MBL substratÄ± <strong>deÄŸildir</strong> â€” bu, tedavinin kilit noktasÄ±dÄ±r.<span class="cite">[1]</span></p>
        </div>
      </div>
      
      <h2 class="sec-head">BaÅŸlÄ±ca MBL Tipleri</h2>
      <table>
        <tr><th>Gen</th><th>Karbapenemaz Tipi</th><th>SÄ±k GÃ¶rÃ¼ldÃ¼ÄŸÃ¼ TÃ¼r</th><th>CoÄŸrafi DaÄŸÄ±lÄ±m</th><th>Klinik Ã–nem</th></tr>
        <tr><td><span class="badge badge-red">NDM</span></td><td>MBL (SÄ±nÄ±f B)</td><td>Enterobacterales, K. pneumoniae</td><td>KÃ¼resel, GÃ¼ney Asya kaynaklÄ±</td><td class="bad">Ã‡ok yÃ¼ksek</td></tr>
        <tr><td><span class="badge badge-orange">VIM</span></td><td>MBL (SÄ±nÄ±f B)</td><td>P. aeruginosa, Enterobacterales</td><td>Avrupa, TÃ¼rkiye sÄ±k</td><td class="bad">Ã‡ok yÃ¼ksek</td></tr>
        <tr><td><span class="badge badge-gold">IMP</span></td><td>MBL (SÄ±nÄ±f B)</td><td>P. aeruginosa, A. baumannii</td><td>Asya-Pasifik</td><td class="neu">YÃ¼ksek</td></tr>
        <tr><td><span class="badge badge-blue">SPM</span></td><td>MBL (SÄ±nÄ±f B)</td><td>P. aeruginosa</td><td>Brezilya</td><td class="neu">Orta</td></tr>
        <tr><td><span class="badge badge-green">GIM</span></td><td>MBL (SÄ±nÄ±f B)</td><td>P. aeruginosa</td><td>Almanya, Seyrek</td><td class="good">DÃ¼ÅŸÃ¼k</td></tr>
      </table>
      <p>TÃ¼rkiye'de P. aeruginosa izolatlarÄ±nda VIM en sÄ±k izole edilen MBL tipidir; Enterobacterales'te ise NDM son yÄ±llarda belirgin ÅŸekilde artmaktadÄ±r.<span class="cite">[3]</span></p>
      
      <h2 class="sec-head">Aztreonam Paradoksu</h2>
      <div class="card success">
        <p>MBL'ler aztreonama (monobaktam) <strong>etki etmez</strong> â€” Ã§Ã¼nkÃ¼ aztreonamÄ±n kimyasal yapÄ±sÄ±nda Î²-laktam halkasÄ±nÄ±n MBL aktif bÃ¶lgesine baÄŸlanmasÄ±nÄ± engelleyen bir Ã¶zellik vardÄ±r. Bu durum CZA+aztreonam kombinasyonu tedavisinin temelini oluÅŸturur.<span class="cite">[1]</span></p>
        <p>âš ï¸ <strong>UyarÄ±:</strong> MBL taÅŸÄ±yan izolatlarÄ±n birÃ§oÄŸu eÅŸ zamanlÄ± ESBL veya AmpC de taÅŸÄ±r. Bu durumda aztreonam direnÃ§ kazanabilir â€” kombine tedavide CZA (avibaktam) ESBL/AmpC'yi baskÄ±larken aztreonam MBL'nin Ã¼rettiÄŸi karbapenemleri de etkisiz kÄ±lmaya devam eder.</p>
      </div>
    </div>

    <!-- 02 mCIM -->
    <div class="section" id="sec-mcim">
      <div class="page-tag">02 â€” Fenotipik Test</div>
      <h1 class="page-title">mCIM <span>Testi</span></h1>
      <p class="page-sub">Modified Carbapenem Inactivation Method â€” "Karbapenemaz var mÄ±?" sorusuna yanÄ±t verir.</p>
      
      <h2 class="sec-head">Temel Prensip</h2>
      <p>mCIM, bakterinin karbapenemi parÃ§alayÄ±p parÃ§alayamadÄ±ÄŸÄ±nÄ± dolaylÄ± yoldan Ã¶lÃ§er.<span class="cite">[4]</span> Test mantÄ±ÄŸÄ± ÅŸÃ¶yledir:</p>
      <div class="flow">
        <div class="flow-box start">Test edilecek bakteri + Meropenem diski birlikte bekletilir (35Â°C, 4 saat)</div>
        <div class="flow-arrow"></div>
        <div class="flow-box decision">Disk indikatÃ¶r E. coli Ã§im plaÄŸÄ±na yerleÅŸtirilir (18-24 saat)</div>
        <div class="flow-arrow"></div>
        <div class="flow-branch">
          <div class="flow-branch-col">
            <div class="flow-label">Zon â‰¤ 19 mm</div>
            <div class="flow-box mbl">mCIM POZÄ°TÄ°F<br><small>Karbapenemaz VAR</small></div>
          </div>
          <div class="flow-branch-col">
            <div class="flow-label">Zon â‰¥ 25 mm</div>
            <div class="flow-box pos">mCIM NEGATÄ°F<br><small>Karbapenemaz YOK</small></div>
          </div>
          <div class="flow-branch-col">
            <div class="flow-label">20â€“24 mm</div>
            <div class="flow-box ser">Belirsiz â†’ Tekrar</div>
          </div>
        </div>
      </div>
      
      <h2 class="sec-head">Yorumlama (CLSI M100-2024)</h2>
      <table>
        <tr><th>Ä°nhibisyon Zonu</th><th>SonuÃ§</th><th>Yorum</th></tr>
        <tr><td>â‰¤ 19 mm</td><td class="bad">Pozitif</td><td>Karbapenemaz mevcut â€” eCIM ile tip belirle</td></tr>
        <tr><td>20â€“24 mm</td><td class="neu">Belirsiz</td><td>Tekrar et; kalite kontrol, inokulum, inkÃ¼basyon kontrol</td></tr>
        <tr><td>â‰¥ 25 mm</td><td class="good">Negatif</td><td>Karbapenemaz yok; ESBL/AmpC + porin kaybÄ± dÃ¼ÅŸÃ¼n</td></tr>
      </table>
      <p style="color:var(--text3);font-size:13px">*CLSI M100 34. baskÄ± (2024) kriterleri.<span class="cite">[4]</span> EUCAST yaklaÅŸÄ±mÄ± bazÄ± eÅŸik deÄŸerlerde farklÄ±lÄ±k gÃ¶sterebilir.</p>
      
      <h2 class="sec-head">SÄ±nÄ±rlamalar</h2>
      <div class="card warn">
        <p><strong>mCIM yalnÄ±zca karbapenemaz varlÄ±ÄŸÄ±nÄ± saptar; tipini sÃ¶ylemez.</strong> Pozitif sonuÃ§ alÄ±ndÄ±ÄŸÄ±nda eCIM veya kombine disk ile MBL/Serin karbapenemaz ayrÄ±mÄ± mutlaka yapÄ±lmalÄ±dÄ±r.<span class="cite">[4]</span></p>
      </div>
    </div>

    <!-- 03 eCIM -->
    <div class="section" id="sec-ecim">
      <div class="page-tag">03 â€” Metal BaÄŸÄ±mlÄ±lÄ±k Testi</div>
      <h1 class="page-title">eCIM <span>Testi</span></h1>
      <p class="page-sub">EDTA-modified Carbapenem Inactivation Method â€” "Bu karbapenemaz MBL mi?" sorusunu yanÄ±tlar. CLSI'nin pratik altÄ±n kuralÄ±dÄ±r.<span class="cite">[4]</span></p>
      
      <h2 class="sec-head">EDTA'nÄ±n RolÃ¼</h2>
      <div class="card-grid">
        <div class="card highlight">
          <h3 class="sub-head">NasÄ±l Ã‡alÄ±ÅŸÄ±r?</h3>
          <p>EDTA gÃ¼Ã§lÃ¼ bir metal ÅŸelatÃ¶rÃ¼dÃ¼r. MBL enzimi aktif bÃ¶lgesindeki ZnÂ²âº'ye muhtaÃ§tÄ±r. EDTA â†’ ZnÂ²âº baÄŸlar â†’ MBL deaktive olur â†’ Karbapenem artÄ±k parÃ§alanmaz â†’ Disk etkin kalÄ±r â†’ Ä°nhibisyon zonu bÃ¼yÃ¼r.<span class="cite">[3]</span></p>
        </div>
        <div class="card gold">
          <h3 class="sub-head">Kritik EÅŸik</h3>
          <div class="formula"><span class="big">eCIM âˆ’ mCIM â‰¥ 5 mm</span><br><small style="color:var(--text2);font-size:12px">= MBL pozitif</small></div>
          <p style="font-size:13px">Bu fark CLSI tarafÄ±ndan pratik kesim noktasÄ± olarak belirlenmiÅŸtir.<span class="cite">[4]</span></p>
        </div>
      </div>
      
      <h2 class="sec-head">mCIM + eCIM Birlikte Yorumlama</h2>
      <table>
        <tr><th>mCIM</th><th>eCIMâ€“mCIM FarkÄ±</th><th>Yorum</th></tr>
        <tr><td class="good">Negatif</td><td>â€”</td><td>Karbapenemaz yok â†’ Rapor et (ESBL/AmpC + porin)</td></tr>
        <tr><td class="bad">Pozitif</td><td class="bad">â‰¥ 5 mm</td><td>MBL pozitif (NDM/VIM/IMP olasÄ±)</td></tr>
        <tr><td class="bad">Pozitif</td><td class="neu">< 5 mm</td><td>Serin karbapenemaz (KPC veya OXA-tipi)</td></tr>
        <tr><td class="bad">Pozitif</td><td>Belirsiz</td><td>Tekrar et; kombine disk veya molekÃ¼ler panel</td></tr>
      </table>
      
      <h2 class="sec-head">Test PerformansÄ±</h2>
      <p>Ã‡eÅŸitli Ã§alÄ±ÅŸmalarÄ±n meta-analizleri, mCIM'in karbapenemaz saptamada duyarlÄ±lÄ±ÄŸÄ±nÄ± %93â€“98 arasÄ±nda gÃ¶stermiÅŸtir. eCIM eklenerek MBL ayrÄ±mÄ±nda Ã¶zgÃ¼llÃ¼k %90'Ä±n Ã¼zerine Ã§Ä±kmaktadÄ±r.<span class="cite">[3]</span> Ancak Acinetobacter izolatlarÄ±nda EDTA hÃ¼cre duvarÄ± permeabilitesini deÄŸiÅŸtirerek yalancÄ± pozitiflik yaratabilir â€” bu kritik tuzakta ayrÄ±ntÄ± iÃ§in "Lab TuzaklarÄ±" bÃ¶lÃ¼mÃ¼ne bakÄ±nÄ±z.</p>
    </div>

    <!-- 04 KOMBÄ°NE DÄ°SK -->
    <div class="section" id="sec-kombine">
      <div class="page-tag">04 â€” Fenotipik Test</div>
      <h1 class="page-title">Ä°nhibitÃ¶rlÃ¼ <span>Kombine Disk</span></h1>
      <p class="page-sub">AynÄ± prensip, farklÄ± format. Meropenem tek disk ile inhibitÃ¶rlÃ¼ disk karÅŸÄ±laÅŸtÄ±rÄ±larak enzim "parmak izi" Ã§Ä±karÄ±lÄ±r.</p>
      
      <h2 class="sec-head">KullanÄ±lan Ä°nhibitÃ¶rler</h2>
      <div class="card-grid">
        <div class="card highlight">
          <h3 class="sub-head" style="color:var(--accent)">ğŸ”µ EDTA / DPA</h3>
          <p><strong>Hedef:</strong> MBL (SÄ±nÄ±f B)<br>Ã‡inko ÅŸelasyonu ile MBL'yi baskÄ±lar. Zon artÄ±ÅŸÄ± â‰¥ belirlenen eÅŸik â†’ MBL pozitif.<span class="cite">[4]</span></p>
        </div>
        <div class="card gold">
          <h3 class="sub-head" style="color:var(--accent4)">ğŸŸ¡ Boronik Asit</h3>
          <p><strong>Hedef:</strong> KPC (SÄ±nÄ±f A)<br>Serin aktif bÃ¶lgesini kovalent inhibe eder. Zon artÄ±ÅŸÄ± â†’ KPC pozitif.<span class="cite">[3]</span></p>
        </div>
        <div class="card success">
          <h3 class="sub-head" style="color:var(--accent3)">ğŸŸ¢ Kloxasilin</h3>
          <p><strong>Hedef:</strong> AmpC (SÄ±nÄ±f C)<br>AmpC'yi baskÄ±lar. Zon artÄ±ÅŸÄ± â†’ AmpC katkÄ±sÄ± var (karbapenemaz deÄŸil).<span class="cite">[3]</span></p>
        </div>
        <div class="card warn">
          <h3 class="sub-head" style="color:var(--accent2)">ğŸŸ  Avibaktam</h3>
          <p><strong>Hedef:</strong> KPC, OXA-48 (SÄ±nÄ±f A/D)<br>MBL'yi <strong>inhibe etmez</strong> â€” bu negatif sonuÃ§ MBL'yi iÅŸaret eder.<span class="cite">[1]</span></p>
        </div>
      </div>
      
      <h2 class="sec-head">mCIM/eCIM vs Kombine Disk</h2>
      <table>
        <tr><th>Ã–zellik</th><th>mCIM/eCIM</th><th>Kombine Disk</th></tr>
        <tr><td>Standardizasyon</td><td class="good">YÃ¼ksek (CLSI Ã¶nerir)</td><td class="neu">Orta (kit baÄŸÄ±mlÄ±)</td></tr>
        <tr><td>GÃ¼venilirlik</td><td class="good">Daha gÃ¼venilir</td><td class="neu">Deneyim gerektirir</td></tr>
        <tr><td>HÄ±z</td><td class="neu">~24 saat</td><td class="good">~18 saat</td></tr>
        <tr><td>Maliyet</td><td class="neu">Orta</td><td class="good">DÃ¼ÅŸÃ¼k</td></tr>
        <tr><td>KullanÄ±m yeri</td><td>DoÄŸrulama</td><td>HÄ±zlÄ± tarama</td></tr>
      </table>
      <div class="card">
        <p><strong>Pratik yaklaÅŸÄ±m:</strong> Ã‡oÄŸu rutin laboratuvar â†’ tarama iÃ§in kombine disk, doÄŸrulama iÃ§in mCIM/eCIM kombinasyonunu tercih eder.<span class="cite">[4]</span></p>
      </div>
    </div>

    <!-- 05 ALGORÄ°TMA -->
    <div class="section" id="sec-algoritma">
      <div class="page-tag">05 â€” TanÄ± AkÄ±ÅŸÄ±</div>
      <h1 class="page-title">Fenotipik TanÄ± <span>AlgoritmasÄ±</span></h1>
      <p class="page-sub">Enterobacterales, P. aeruginosa ve Acinetobacter spp. iÃ§in adÄ±m adÄ±m MBL tanÄ± akÄ±ÅŸÄ± (EUCAST/CLSI sentezi).<span class="cite">[3,4]</span></p>
      
      <div class="flow">
        <div class="flow-box start" style="border-color:var(--accent)">1ï¸âƒ£ TÃ¼r tanÄ±mlandÄ±: Enterobacterales / P. aeruginosa / Acinetobacter spp.</div>
        <div class="flow-arrow"></div>
        <div class="flow-box decision">2ï¸âƒ£ Rutin duyarlÄ±lÄ±k (disk/MÄ°K)<br><small>MEM / IPM / ETP'de â†“ duyarlÄ±lÄ±k?</small></div>
        <div class="flow-arrow"></div>
        <div class="flow-branch">
          <div class="flow-branch-col">
            <div class="flow-label">HAYIR</div>
            <div class="flow-box neg">Rutin Rapor<br><small>MBL dÃ¼ÅŸÃ¼nme</small></div>
          </div>
          <div class="flow-branch-col">
            <div class="flow-label">EVET</div>
            <div class="flow-box pos">Karbapenemaz TaramasÄ±</div>
          </div>
        </div>
        <div class="flow-arrow"></div>
        <div class="flow-box decision">3ï¸âƒ£ mCIM testi</div>
        <div class="flow-arrow"></div>
        <div class="flow-branch">
          <div class="flow-branch-col">
            <div class="flow-label">Negatif</div>
            <div class="flow-box neg">Karbapenemaz YOK<br><small>ESBL/AmpC + Porin kaybÄ±?</small></div>
          </div>
          <div class="flow-branch-col">
            <div class="flow-label">Pozitif</div>
            <div class="flow-box decision">4ï¸âƒ£ eCIM / Kombine Disk<br><small>Zon artÄ±ÅŸÄ± â‰¥5 mm?</small></div>
          </div>
        </div>
        <div class="flow-arrow"></div>
        <div class="flow-branch">
          <div class="flow-branch-col">
            <div class="flow-label">EVET (â‰¥5 mm)</div>
            <div class="flow-box mbl">MBL POZÄ°TÄ°F âœ“<br><small>NDM/VIM/IMP olasÄ±</small></div>
          </div>
          <div class="flow-branch-col">
            <div class="flow-label">HAYIR (&lt;5 mm)</div>
            <div class="flow-box ser">Serin Karbapenemaz<br><small>KPC / OXA-48-like</small></div>
          </div>
        </div>
        <div class="flow-arrow"></div>
        <div class="flow-box start" style="border-color:var(--success);color:var(--success)">6ï¸âƒ£ Rapor + Enfeksiyon Kontrol Bildirimi + MolekÃ¼ler DoÄŸrulama Ã–ner</div>
      </div>
      
      <h2 class="sec-head">TÃ¼r BazlÄ± Yorum</h2>
      <table>
        <tr><th>Organizma</th><th>En SÄ±k MBL Tipi</th><th>Not</th></tr>
        <tr><td>Enterobacterales</td><td><span class="badge badge-red">NDM</span> <span class="badge badge-orange">VIM</span> <span class="badge badge-gold">IMP</span></td><td>NDM GÃ¼ney Asya kÃ¶kenli; plazmid taÅŸÄ±nÄ±mÄ± yÃ¼ksek</td></tr>
        <tr><td>P. aeruginosa</td><td><span class="badge badge-orange">VIM</span> <span class="badge badge-gold">IMP</span></td><td>VIM TÃ¼rkiye/Avrupa'da sÄ±k; cefiderocol etkin kalabilir</td></tr>
        <tr><td>Acinetobacter spp.</td><td><span class="badge badge-orange">VIM</span> <span class="badge badge-gold">IMP</span></td><td>OXA tipler Ã§ok daha sÄ±k; EDTA sinerjisi dikkatli yorumla</td></tr>
      </table>
    </div>

    <!-- 06 MBL vs KPC -->
    <div class="section" id="sec-mblvskpc">
      <div class="page-tag">06 â€” KarÅŸÄ±laÅŸtÄ±rma</div>
      <h1 class="page-title">MBL <span>vs</span> KPC</h1>
      <p class="page-sub">Bu ayrÄ±m tedavi algoritmasÄ±nÄ± kÃ¶kten deÄŸiÅŸtirir. YanlÄ±ÅŸ sÄ±nÄ±flama = yanlÄ±ÅŸ tedavi. Bu yÃ¼zden fenotipik testler sadece laboratuvar iÅŸi deÄŸil, klinisyen kararÄ±nÄ±n kalbidir.</p>
      
      <h2 class="sec-head">Temel KarÅŸÄ±laÅŸtÄ±rma</h2>
      <table>
        <tr><th>Ã–zellik</th><th>MBL (SÄ±nÄ±f B)</th><th>KPC (SÄ±nÄ±f A)</th><th>OXA-48 (SÄ±nÄ±f D)</th></tr>
        <tr><td>Ambler SÄ±nÄ±fÄ±</td><td>B</td><td>A</td><td>D</td></tr>
        <tr><td>Katalitik merkez</td><td>Ã‡inko (ZnÂ²âº)</td><td>Serin</td><td>Serin</td></tr>
        <tr><td>EDTA/DPA sinerjisi</td><td class="good">Var (inhibe eder)</td><td class="bad">Yok</td><td class="bad">Yok</td></tr>
        <tr><td>Avibaktam</td><td class="bad">Ä°nhibe etmez</td><td class="good">Ä°nhibe eder</td><td class="good">Ä°nhibe eder</td></tr>
        <tr><td>Aztreonam hidrolizi</td><td class="good">Yapmaz</td><td class="bad">Yapar</td><td class="bad">Minimal</td></tr>
        <tr><td>mCIM/eCIM</td><td>mCIM(+), eCIM(+)</td><td>mCIM(+), eCIM(âˆ’)</td><td>mCIM genelde zayÄ±f</td></tr>
        <tr><td>Tedavi seÃ§imi</td><td>CZA+ATM / Cefiderocol</td><td>CZA veya I/R</td><td>CZA, Temocillin</td></tr>
      </table>
      <p>OXA-48-benzeri enzimler fenotipik testlerde zayÄ±f sinyal verir; karbapenem direnci gÃ¶rece dÃ¼ÅŸÃ¼k seyreder ve taramada kaÃ§abilir.<span class="cite">[3]</span> Bu nedenle "karbapenem duyarlÄ± gÃ¶rÃ¼nen ama karbapenemaz taÅŸÄ±yan" olgular OXA-48 aÃ§Ä±sÄ±ndan risk deÄŸerlendirmesi gerektirir.</p>
      
      <h2 class="sec-head">Neden Bu Kadar Kritik?</h2>
      <div class="card-grid">
        <div class="card mbl" style="border-color:var(--danger)">
          <h3 class="sub-head" style="color:var(--danger)">MBL Tedavisinde KPC Ä°lacÄ± KullanÄ±rsanÄ±z</h3>
          <p>Avibaktam (CZA) MBL'yi <strong>inhibe etmez</strong>. CZA monoterapisi MBL izolatÄ±nda baÅŸarÄ±sÄ±z olur. Bu, antibiyotik gecikmesi ve mortalite artÄ±ÅŸÄ± anlamÄ±na gelir.<span class="cite">[1]</span></p>
        </div>
        <div class="card success">
          <h3 class="sub-head" style="color:var(--accent3)">DoÄŸru AyrÄ±m SaÄŸladÄ±ÄŸÄ±nda</h3>
          <p>MBL â†’ CZA + aztreonam kombinasyonu. Avibaktam ESBL/AmpC'yi baskÄ±larken aztreonam MBL'li ortamda aktif kalÄ±r. Klinik Ã§alÄ±ÅŸmalar bu kombinin etkinliÄŸini gÃ¶stermiÅŸtir.<span class="cite">[1]</span></p>
        </div>
      </div>
    </div>

    <!-- 07 TEDAVÄ° -->
    <div class="section" id="sec-tedavi">
      <div class="page-tag">07 â€” GÃ¼ncel Tedavi</div>
      <h1 class="page-title">Tedavi <span>AlgoritmasÄ±</span></h1>
      <p class="page-sub">IDSA AMR KÄ±lavuzu 2024 ve ESCMID MDR-GNB Rehberi 2022 doÄŸrultusunda.<span class="cite">[1,2]</span></p>
      
      <h2 class="sec-head">CRE / Enterobacterales â€” MBL (NDM/VIM/IMP)</h2>
      <div class="card highlight">
        <table>
          <tr><th>Ã–ncelik</th><th>Rejim</th><th>KÄ±lavuz Ã–nerisi</th></tr>
          <tr><td><span class="badge badge-green">1. Tercih</span></td><td><strong>Ceftazidim-avibaktam + Aztreonam</strong><br><small style="color:var(--text3)">(CZA + ATM)</small></td><td class="good">GÃ¼Ã§lÃ¼ (IDSA 2024)<span class="cite">[1]</span></td></tr>
          <tr><td><span class="badge badge-green">1. Tercih</span></td><td><strong>Cefiderocol</strong></td><td class="good">GÃ¼Ã§lÃ¼ (IDSA 2024)<span class="cite">[1]</span></td></tr>
          <tr><td><span class="badge badge-gold">Alternatif</span></td><td>Tigecycline / Eravacycline<br><small style="color:var(--text3)">(MÄ°K ve odak uygunsa)</small></td><td class="neu">KoÅŸullu Ã¶neri<span class="cite">[2]</span></td></tr>
          <tr><td><span class="badge badge-gold">Alternatif</span></td><td>Aminoglikozid (DuyarlÄ±ysa)<br><small style="color:var(--text3)">(Amikacin sÄ±klÄ±kla korunur)</small></td><td class="neu">KoÅŸullu Ã¶neri<span class="cite">[2]</span></td></tr>
          <tr><td><span class="badge badge-orange">Kurtarma</span></td><td>Fosfomycin (kombine, idrar dÄ±ÅŸÄ±)</td><td class="neu">SÄ±nÄ±rlÄ± veri<span class="cite">[2]</span></td></tr>
        </table>
      </div>
      
      <h2 class="sec-head">DTR P. aeruginosa â€” MBL OlasÄ±ysa</h2>
      <div class="card warn">
        <p>C/T (ceftolozane-tazobaktam), CZA, imipenem/relebaktam'a direnÃ§ + karbapenemaz varlÄ±ÄŸÄ± â†’ <strong>MBL dÃ¼ÅŸÃ¼n.</strong><span class="cite">[1]</span> Ã‡oÄŸu MBL P. aeruginosa izolatÄ± cefiderocole duyarlÄ± kalmaktadÄ±r. Ancak MÄ°K doÄŸrulamasÄ± ÅŸarttÄ±r.</p>
        <table>
          <tr><th>SeÃ§enek</th><th>AÃ§Ä±klama</th></tr>
          <tr><td><span class="badge badge-green">Cefiderocol</span></td><td>DTR-PsA'da tercih; MBL varlÄ±ÄŸÄ±nda Ã§oÄŸu izolat duyarlÄ±<span class="cite">[1]</span></td></tr>
          <tr><td><span class="badge badge-blue">CZA + ATM</span></td><td>Ko-enzim (ESBL/AmpC) varsa; PsA'da veri sÄ±nÄ±rlÄ±</td></tr>
          <tr><td><span class="badge badge-gold">Aminoglikozid</span></td><td>DuyarlÄ± ise kombine olarak eklenebilir</td></tr>
        </table>
      </div>
      
      <h2 class="sec-head">Genel Prensipler</h2>
      <div class="card">
        <p><strong>Odak kontrolÃ¼ kritiktir</strong> â€” antibiyotik seÃ§imi kadar Ã¶nemlidir. Kateter, dren, cerrahi kaynak kontrol edilmeden antibiyotik baÅŸarÄ±sÄ± sÄ±nÄ±rlÄ± kalÄ±r.<span class="cite">[2]</span></p>
        <p><strong>PK/PD optimizasyonu:</strong> Karbapenem korunuyorsa uzatÄ±lmÄ±ÅŸ infÃ¼zyon (%T>MÄ°K maksimizasyonu) uygulanmalÄ±dÄ±r. Tigecycline gibi ilaÃ§lar iÃ§in yÃ¼kleme dozu ve yÃ¼ksek idame dozu deÄŸerlendirilmelidir.<span class="cite">[1]</span></p>
        <p><strong>MÄ°K bazlÄ± karar:</strong> Yerel antibiyogram ve bireysel MÄ°K deÄŸerleri tÃ¼m seÃ§im kararlarÄ±nÄ±n temeli olmalÄ±dÄ±r. KÄ±lavuz Ã¶nerileri global veriye dayanÄ±r; yerel uyarlama zorunludur.</p>
      </div>
    </div>

    <!-- 08 TUZAKLAR -->
    <div class="section" id="sec-tuzaklar">
      <div class="page-tag">08 â€” Kritik NÃ¼anslar</div>
      <h1 class="page-title">Lab <span>TuzaklarÄ±</span></h1>
      <p class="page-sub">Klinik mikrobiyolojinin karanlÄ±k bÃ¼yÃ¼sÃ¼. Bu beÅŸ tuzak en sÄ±k yanlÄ±ÅŸ yorumlarÄ±n kaynaÄŸÄ±dÄ±r.</p>
      
      <div class="card warn" style="margin-bottom:16px">
        <h3 class="sub-head">âš ï¸ Tuzak 1 â€” Karbapenem â†“ DuyarlÄ±lÄ±k â‰  Karbapenemaz</h3>
        <p>Karbapenem MÄ°K yÃ¼ksekliÄŸi veya zon kÃ¼Ã§Ã¼klÃ¼ÄŸÃ¼ her zaman karbapenemaz varlÄ±ÄŸÄ±nÄ± gÃ¶stermez. <strong>ESBL/AmpC + dÄ±ÅŸ zar proteini (porin) kaybÄ±</strong> karbapenem direncine yol aÃ§abilir ama hiÃ§bir karbapenemaz yoktur.<span class="cite">[3]</span> Bu durumda mCIM negatif gelir. Karbapenemaz olduÄŸunu varsayarak yanlÄ±ÅŸ tedavi verilmesi ciddi bir hatadÄ±r.</p>
      </div>
      
      <div class="card warn">
        <h3 class="sub-head">âš ï¸ Tuzak 2 â€” Acinetobacter'de EDTA YalancÄ± PozitifliÄŸi</h3>
        <p>EDTA, Acinetobacter baumannii'de dÄ±ÅŸ zar permeabilitesini artÄ±rÄ±r ve doÄŸrudan hÃ¼cre duvarÄ± hasarÄ± oluÅŸturur. Bu durum MBL enzim aktivitesinden baÄŸÄ±msÄ±z olarak zon bÃ¼yÃ¼mesine â€” dolayÄ±sÄ±yla <strong>yalancÄ± pozitif eCIM</strong>'e neden olabilir.<span class="cite">[3]</span> Acinetobacter'de MBL saptamasÄ± iÃ§in ek doÄŸrulama (molekÃ¼ler) ÅŸiddetle Ã¶nerilir.</p>
      </div>
      
      <div class="card" style="border-color:var(--accent4);background:rgba(255,209,102,.04);margin-top:16px">
        <h3 class="sub-head">âš ï¸ Tuzak 3 â€” OXA-48-Benzeri KaÃ§abilir</h3>
        <p>OXA-48-like enzimler zayÄ±f karbapenemaz aktivitesi gÃ¶sterir. Karbapenem direnÃ§ dÃ¼zeyi dÃ¼ÅŸÃ¼k, fenotipik testlerde sinyal zayÄ±f olabilir. Ã–zellikle ertapenem dÄ±ÅŸÄ±nda meropenem ve imipenem duyarlÄ±lÄ±ÄŸÄ± korunabilir.<span class="cite">[3]</span> YÃ¼ksek endemik bÃ¶lgelerde OXA-48 risk faktÃ¶rleri varlÄ±ÄŸÄ±nda mutlaka molekÃ¼ler test eklenmeli.</p>
      </div>
      
      <div class="card">
        <h3 class="sub-head">âš ï¸ Tuzak 4 â€” SÄ±nÄ±rda Zon / Pinpoint Koloniler</h3>
        <p>Heterorezistans varlÄ±ÄŸÄ±nda inhibisyon zonu iÃ§inde pinpoint (Ã§ok kÃ¼Ã§Ã¼k) koloniler gÃ¶rÃ¼lebilir. Bu koloniler gÃ¶zden kaÃ§arsa yanlÄ±ÅŸ yorumlama riski yÃ¼ksektir.<span class="cite">[4]</span> Zon iÃ§i herhangi bir koloni tespit edildiÄŸinde test tekrarÄ± ve kalite kontrol gÃ¶zden geÃ§irilmelidir.</p>
      </div>
      
      <div class="card" style="margin-top:16px">
        <h3 class="sub-head">âš ï¸ Tuzak 5 â€” Teknik Hata KaynaklarÄ±</h3>
        <table>
          <tr><th>Kaynak</th><th>Hata</th><th>Ã‡Ã¶zÃ¼m</th></tr>
          <tr><td>Ä°nokulum</td><td>AÅŸÄ±rÄ± veya az inokulum zon boyutunu deÄŸiÅŸtirir</td><td>0.5 McFarland standardÄ±na dikkat</td></tr>
          <tr><td>Ä°nkÃ¼basyon</td><td>SÃ¼re/sÄ±caklÄ±k sapmasÄ± hatalÄ± zon</td><td>35Â°C Â±1, saatleri kaydet</td></tr>
          <tr><td>Disk-Agar temasÄ±</td><td>KÃ¶tÃ¼ temas yalancÄ± bÃ¼yÃ¼k zon</td><td>Disk aplikatÃ¶r veya forseps ile bastÄ±r</td></tr>
          <tr><td>EDTA dozu</td><td>Yetersiz/fazla EDTA sinyal kaybÄ±/yalancÄ±(+)</td><td>Kit talimatÄ±na ve validasyon sonuÃ§larÄ±na uyu</td></tr>
          <tr><td>Kalite kontrol</td><td>Referans suÅŸ kullanÄ±lmazsa doÄŸrulama yok</td><td>Her Ã§alÄ±ÅŸmada (+) ve (âˆ’) kontrol</td></tr>
        </table>
      </div>
    </div>

    <!-- 09 MOLEKÃœLER -->
    <div class="section" id="sec-molekuler">
      <div class="page-tag">09 â€” MolekÃ¼ler TanÄ±</div>
      <h1 class="page-title">MolekÃ¼ler <span>Panel</span></h1>
      <p class="page-sub">Fenotipik testler ÅŸÃ¼pheyi doÄŸurur; molekÃ¼ler testler suÃ§luyu yakalar. Ne zaman PCR/panel gerekir?</p>
      
      <h2 class="sec-head">Endikasyonlar</h2>
      <table>
        <tr><th>Durum</th><th>Neden?</th><th>Ã–neri</th></tr>
        <tr><td>Bakteriyemi / Sepsis</td><td>HÄ±zlÄ± hedef tedavi iÃ§in saat kritiktir</td><td class="good">GÃ¼Ã§lÃ¼ endikasyon<span class="cite">[1]</span></td></tr>
        <tr><td>SalgÄ±n / Klaster</td><td>Epidemiyolojik tiplendirme, IPC kararÄ±</td><td class="good">GÃ¼Ã§lÃ¼ endikasyon</td></tr>
        <tr><td>Kolonizasyon TaramasÄ±</td><td>Risk altÄ±ndaki hastalar, nakil Ã¶ncesi</td><td class="neu">KoÅŸullu</td></tr>
        <tr><td>Fenotipik Belirsizlik</td><td>mCIM/eCIM Ã§eliÅŸkili veya teknik sorun</td><td class="good">GÃ¼Ã§lÃ¼ endikasyon<span class="cite">[3]</span></td></tr>
        <tr><td>Terapi SeÃ§imi Kritik</td><td>MBL vs KPC vs OXA-48 ayrÄ±mÄ± ÅŸart</td><td class="good">GÃ¼Ã§lÃ¼ endikasyon<span class="cite">[1]</span></td></tr>
        <tr><td>Acinetobacter ÅŸÃ¼phesi</td><td>EDTA yalancÄ±(+) riski var</td><td class="good">GÃ¼Ã§lÃ¼ endikasyon<span class="cite">[3]</span></td></tr>
      </table>
      
      <h2 class="sec-head">Mevcut Paneller ve YÃ¶ntemler</h2>
      <div class="card-grid">
        <div class="card highlight">
          <h3 class="sub-head">Multipleks PCR</h3>
          <p>NDM, VIM, IMP, KPC, OXA-48'i tek reaksiyonda saptar. BirÃ§ok ticari panel mevcuttur. SonuÃ§ 2â€“4 saat.<span class="cite">[3]</span></p>
        </div>
        <div class="card">
          <h3 class="sub-head">Dizi Analizi (Sekans)</h3>
          <p>Varyant dÃ¼zeyinde tiplendirme gerektiÄŸinde (VIM-1 vs VIM-2, epidemiyoloji). GÃ¼nler alabilir.</p>
        </div>
        <div class="card gold">
          <h3 class="sub-head">NG-CARBA / Lateral Flow</h3>
          <p>Yeni nesil hÄ±zlÄ± immunokromatografik test. SonuÃ§ 15â€“30 dk. DoÄŸruluk verisi birikmektedir.<span class="cite">[3]</span></p>
        </div>
        <div class="card">
          <h3 class="sub-head">MALDI-TOF YaklaÅŸÄ±mÄ±</h3>
          <p>Karbapenemaz hidrolizi MALDI-TOF ile doÄŸrudan tespit. AraÅŸtÄ±rma evresi; henÃ¼z rutin deÄŸil.<span class="cite">[3]</span></p>
        </div>
      </div>
      
      <h2 class="sec-head">Raporlama</h2>
      <div class="card success">
        <p>Fenotipik test sonucu ÅŸÃ¶yle raporlanmalÄ±dÄ±r: <strong>"Fenotipik olarak MBL Ã¼retimiyle uyumlu karbapenemaz saptandÄ±; genetik doÄŸrulama Ã¶nerilir."</strong> MolekÃ¼ler onay sonucunda gen adÄ± (NDM, VIM vb.) rapora eklenmelidir.</p>
        <p>TÃ¼m karbapenemaz saptama vakalarÄ± <strong>enfeksiyon kontrol birimine bildirimi</strong> gerektirir â€” bu akademik deÄŸil, zorunlu bir klinik aksiyondur.<span class="cite">[2]</span></p>
      </div>
    </div>

    <!-- 10 QUIZ -->
    <div class="section" id="sec-quiz">
      <div class="page-tag">10 â€” Bilgi SÄ±navÄ±</div>
      <h1 class="page-title">Quiz <span>ZamanÄ±</span></h1>
      <p class="page-sub">10 klinik soru. SÃ¼re baskÄ±sÄ± yok â€” anlayarak cevaplayÄ±n.</p>
      
      <div id="quizArea"></div>
      <div id="quizHistory" style="margin-top:24px"></div>
    </div>

    <!-- REFS -->
    <div class="section" id="sec-refs">
      <div class="page-tag">Referanslar</div>
      <h1 class="page-title">KaynakÃ§a</h1>
      <p class="page-sub">Bu modÃ¼lde kullanÄ±lan gÃ¼ncel literatÃ¼r ve kÄ±lavuzlar.</p>
      <div class="ref-list">
        <div class="ref-item"><span class="ref-num">[1]</span><span>IDSA Antimicrobial Resistance Guidance Panel. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum Î²-Lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). <em>Clin Infect Dis.</em> 2024 (GÃ¼ncel versiyon). https://www.idsociety.org/practice-guideline/amr-guidance/</span></div>
        <div class="ref-item"><span class="ref-num">[2]</span><span>Tamma PD, Aitken SL, Bonomo RA, et al. ESCMID/ASM Guideline for the Treatment of Infections Caused by Multidrug-Resistant Gram-Negative Bacteria. <em>Clin Infect Dis.</em> 2022;75(Suppl 2):S169â€“S228. doi:10.1093/cid/ciac050</span></div>
        <div class="ref-item"><span class="ref-num">[3]</span><span>Simner PJ, Patel R, Carroll KC. Carbapenemase Detection: A Practical Guide for Clinical Microbiology Laboratories. <em>Clin Microbiol Rev.</em> 2024;37(1):e0006123. doi:10.1128/cmr.00061-23</span></div>
        <div class="ref-item"><span class="ref-num">[4]</span><span>Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. <em>CLSI Supplement M100.</em> 34th ed. Wayne, PA: CLSI; 2024. (mCIM/eCIM protokolleri dahil)</span></div>
      </div>
      <div class="card" style="margin-top:24px;border-color:var(--border)">
        <p style="font-size:13px;color:var(--text3)"><strong>UyarÄ±:</strong> Bu modÃ¼l eÄŸitim amaÃ§lÄ±dÄ±r. Hasta bazlÄ± kararlar iÃ§in yerel antibiyogram verileri, odak kontrolÃ¼ deÄŸerlendirmesi ve enfeksiyon hastalÄ±klarÄ± konsÃ¼ltasyonu esastÄ±r. Dozlar, kÄ±lavuzlar ve MÄ°K kesim deÄŸerleri deÄŸiÅŸkenlik gÃ¶sterebilir; gÃ¼ncel kaynaklarÄ± takip ediniz.</p>
      </div>
    </div>

  </div><!-- /main -->
</div><!-- /app -->

<script>
// ===================== DATA =====================
const QUIZ_QUESTIONS = [
  {
    q: "mCIM testinde meropenem diski 17 mm zon oluÅŸturdu. Bu sonuÃ§ ne anlama gelir?",
    opts: ["Karbapenemaz yok; rutin rapor yeterli","mCIM pozitif; karbapenemaz var â€” eCIM ile devam et","mCIM belirsiz; tekrar gerekli","MBL kesin pozitif"],
    ans: 1,
    exp: "CLSI M100 2024'e gÃ¶re zon â‰¤19 mm â†’ mCIM pozitif, karbapenemaz varlÄ±ÄŸÄ±nÄ± gÃ¶sterir. Ancak tip belirlemek iÃ§in eCIM gerekir. Zon â‰¥25 mm negatif, 20â€“24 mm belirsizdir.[4]"
  },
  {
    q: "eCIM testinde mCIM ile karÅŸÄ±laÅŸtÄ±rÄ±ldÄ±ÄŸÄ±nda zon 7 mm bÃ¼yÃ¼dÃ¼. Yorumunuz?",
    opts: ["MBL negatif","KPC pozitif","MBL pozitif (metal baÄŸÄ±mlÄ± karbapenemaz)","OXA-48 pozitif"],
    ans: 2,
    exp: "CLSI kriteri: eCIM âˆ’ mCIM â‰¥ 5 mm â†’ MBL pozitif. EDTA Ã§inkoyu ÅŸelate ederek MBL enzimini deaktive eder; zon bÃ¼yÃ¼r. Bu klasik metal baÄŸÄ±mlÄ±lÄ±k kanÄ±tÄ±dÄ±r.[4]"
  },
  {
    q: "MBL pozitif K. pneumoniae bakteriyemisinde hangi antibiyotik rejimine Ã¶ncelik verilir?",
    opts: ["Meropenem yÃ¼ksek doz","Ceftazidim-avibaktam (CZA) monoterapi","Ceftazidim-avibaktam + Aztreonam (CZA+ATM)","Ä°mipenem + kolistin"],
    ans: 2,
    exp: "IDSA AMR KÄ±lavuzu 2024: MBL-CRE iÃ§in CZA+ATM veya cefiderocol tercih edilir. CZA monoterapisi MBL'yi inhibe etmez; avibaktam yalnÄ±zca ESBL/AmpC'yi baskÄ±larken ATM MBL ortamÄ±nda aktif kalÄ±r.[1]"
  },
  {
    q: "Acinetobacter baumannii'de eCIM pozitif bulundu. Hangi Ã¶nemli tuzaÄŸÄ± dÃ¼ÅŸÃ¼nmeliyiz?",
    opts: ["KPC olasÄ±lÄ±ÄŸÄ±","OXA-23 interferansÄ±","EDTA hÃ¼cre duvarÄ± permeabilitesini artÄ±rarak yalancÄ± pozitif verebilir","Aztreonam direnci MBL kanÄ±tÄ±dÄ±r"],
    ans: 2,
    exp: "EDTA Acinetobacter dÄ±ÅŸ zarÄ±nÄ± doÄŸrudan etkiler ve MBL'den baÄŸÄ±msÄ±z zon bÃ¼yÃ¼mesi (yalancÄ± pozitif) oluÅŸturabilir. Acinetobacter'de MBL doÄŸrulamasÄ± iÃ§in molekÃ¼ler test ÅŸiddetle Ã¶nerilir.[3]"
  },
  {
    q: "Karbapenem MÄ°K yÃ¼ksek bulunan bir E. coli izolatÄ±nda mCIM negatif. En olasÄ± aÃ§Ä±klama?",
    opts: ["NDM enzimi var ama test yanlÄ±ÅŸ yapÄ±ldÄ±","ESBL + AmpC + porin (OmpF/OmpC) kaybÄ± kombinasyonu","KPC zayÄ±f fenotip gÃ¶steriyor","VIM enzimi eCIM ile saptanabilir"],
    ans: 1,
    exp: "Karbapenem direnci karbapenemaz olmadan da oluÅŸabilir. ESBL veya AmpC Ã¼retimi + dÄ±ÅŸ zar protein kaybÄ± (porin) kombinasyonu karbapenem MÄ°K'ini artÄ±rÄ±r. mCIM bu durumda negatif kalÄ±r.[3]"
  },
  {
    q: "MBL pozitif P. aeruginosa'da hangi ajan sÄ±klÄ±kla etkinliÄŸini korur?",
    opts: ["Meropenem","Ceftazidim-avibaktam (CZA) monoterapi","Cefiderocol","Ä°mipenem/relebaktam"],
    ans: 2,
    exp: "IDSA 2024: DTR P. aeruginosa + MBL senaryosunda Ã§oÄŸu izolat cefiderocole duyarlÄ± kalmaktadÄ±r. CZA, C/T, ve imipenem/relebaktam MBL P. aeruginosa'da etkin deÄŸildir.[1]"
  },
  {
    q: "Kombine disk yÃ¶nteminde boronik asit ile zon artÄ±ÅŸÄ± gÃ¶zlemlendi. Bu hangi karbapenemaz sÄ±nÄ±fÄ±nÄ± iÅŸaret eder?",
    opts: ["MBL (SÄ±nÄ±f B)","KPC (SÄ±nÄ±f A)","OXA-48 (SÄ±nÄ±f D)","AmpC (SÄ±nÄ±f C)"],
    ans: 1,
    exp: "Boronik asit KPC gibi serin karbapenemaz (SÄ±nÄ±f A) enzimlerini inhibe eder. Zon artÄ±ÅŸÄ± â†’ KPC baskÄ±landÄ± â†’ KPC pozitif. EDTA/DPA ise MBL (SÄ±nÄ±f B) iÃ§in spesifik inhibitÃ¶rdÃ¼r.[3,4]"
  },
  {
    q: "Hangi MBL tipi aztreonamÄ± hidrolize eder?",
    opts: ["NDM","VIM","IMP","HiÃ§biri â€” MBL'ler aztreonama etki etmez"],
    ans: 3,
    exp: "MBL'lerin hiÃ§biri monobaktamlarÄ± (aztreonam) hidrolize etmez â€” bu kimyasal yapÄ±sal bir Ã¶zelliktir. Bu durum CZA+ATM kombinasyonunun temelini oluÅŸturur: CZA ESBL/AmpC'yi, ATM ise MBL Ã¼reticisini etkisiz kÄ±lar.[1]"
  },
  {
    q: "OXA-48 benzeri enzimler fenotipik testlerde hangi zorluÄŸu yaratÄ±r?",
    opts: ["Her zaman mCIM pozitif ve belirgin zon kÃ¼Ã§Ã¼lmesi","ZayÄ±f fenotip; mCIM negatif Ã§Ä±kabilir ve taramada kaÃ§abilir","eCIM ile kolayca saptanÄ±r","Sadece P. aeruginosa'da bulunur"],
    ans: 1,
    exp: "OXA-48-like enzimler zayÄ±f karbapenemaz aktivitesi gÃ¶sterir. Karbapenem direnci (Ã¶zellikle meropenem) dÃ¼ÅŸÃ¼k seyreder; mCIM negatif gelebilir. YÃ¼ksek endemik bÃ¶lgelerde molekÃ¼ler tarama ÅŸarttÄ±r.[3]"
  },
  {
    q: "Bakteriyemi nedeniyle yoÄŸun bakÄ±mdaki hastanÄ±n kan kÃ¼ltÃ¼rÃ¼nde MBL pozitif K. pneumoniae Ã¼remesi rapor edildi. Laboratuvar dÄ±ÅŸÄ±ndaki Ã¶ncelikli adÄ±m ne olmalÄ±dÄ±r?",
    opts: ["Sadece antibiyotik baÅŸla ve bekle","Enfeksiyon kontrol birimine bildir + temas Ã¶nlemleri al","HastayÄ± izole et ama bildirim gerekli deÄŸil","MolekÃ¼ler doÄŸrulama sonuÃ§lanana kadar bekle"],
    ans: 1,
    exp: "Karbapenemaz (Ã¶zellikle MBL) saptanan tÃ¼m olgular enfeksiyon kontrol birimine bildirilmeli ve temas Ã¶nlemleri derhal uygulanmalÄ±dÄ±r. Bu hem ESCMID 2022 hem de ulusal IPC rehberlerinin zorunlu Ã¶nerisidir.[2]"
  }
];

// ===================== STORAGE KEY =====================
let currentUser = '';

function storageKey(k) { return `mbl_${currentUser}_${k}`; }

async function saveScore(s, total) {
  const now = new Date().toLocaleDateString('tr-TR');
  let hist = [];
  try {
    const r = await window.storage.get(storageKey('scoreHist'));
    if (r) hist = JSON.parse(r.value);
  } catch(e) {}
  hist.unshift({ date: now, score: s, total });
  if (hist.length > 10) hist = hist.slice(0, 10);
  try { await window.storage.set(storageKey('scoreHist'), JSON.stringify(hist)); } catch(e) {}
  return hist;
}

async function loadHistory() {
  try {
    const r = await window.storage.get(storageKey('scoreHist'));
    return r ? JSON.parse(r.value) : [];
  } catch(e) { return []; }
}

// ===================== LOGIN =====================
document.getElementById('loginBtn').addEventListener('click', doLogin);
document.getElementById('loginPass').addEventListener('keydown', e => { if(e.key==='Enter') doLogin(); });

function doLogin() {
  const u = document.getElementById('loginUser').value.trim();
  const p = document.getElementById('loginPass').value;
  if (!u) { document.getElementById('loginErr').textContent='KullanÄ±cÄ± adÄ± girin'; return; }
  if (p !== '1234') { document.getElementById('loginErr').textContent='Åifre hatalÄ± (demo: 1234)'; return; }
  currentUser = u;
  document.getElementById('loginScreen').style.display='none';
  document.getElementById('app').style.display='block';
  document.getElementById('userNameEl').textContent = u;
  document.getElementById('avatarEl').textContent = u[0].toUpperCase();
  loadSection('home');
  renderQuiz();
}

document.getElementById('logoutBtn').addEventListener('click', doLogout);

function doLogout() {
  document.getElementById('loginScreen').style.display='flex';
  document.getElementById('app').style.display='none';
  document.getElementById('loginUser').value='';
  document.getElementById('loginPass').value='';
  document.getElementById('loginErr').textContent='';
  stopTTS();
}

// ===================== SECTION DATA =====================
const SECTIONS = [
  { id:'home',      num:'00', label:'Genel BakÄ±ÅŸ' },
  { id:'temel',     num:'01', label:'MBL Nedir?' },
  { id:'mcim',      num:'02', label:'mCIM Testi' },
  { id:'ecim',      num:'03', label:'eCIM Testi' },
  { id:'kombine',   num:'04', label:'Kombine Disk' },
  { id:'algoritma', num:'05', label:'TanÄ± AlgoritmasÄ±' },
  { id:'mblvskpc',  num:'06', label:'MBL vs KPC' },
  { id:'tedavi',    num:'07', label:'Tedavi' },
  { id:'tuzaklar',  num:'08', label:'Lab TuzaklarÄ±' },
  { id:'molekuler', num:'09', label:'MolekÃ¼ler Panel' },
  { id:'quiz',      num:'10', label:'Quiz' },
  { id:'refs',      num:'Ref', label:'Kaynaklar' },
];

// ===================== NAVIGATION =====================
document.getElementById('sideNav').addEventListener('click', e => {
  const item = e.target.closest('.nav-item');
  if (item) loadSection(item.dataset.sec);
});

document.querySelector('.main').addEventListener('click', e => {
  const card = e.target.closest('[data-goto]');
  if (card) loadSection(card.dataset.goto);
  const chip = e.target.closest('.snf-chip[data-sec]');
  if (chip) loadSection(chip.dataset.sec);
});

function buildSectionNavFooter(currentId) {
  const chips = SECTIONS.map(s => {
    const isCurrent = s.id === currentId;
    return `<div class="snf-chip${isCurrent ? ' current' : ''}" data-sec="${s.id}">
      <span class="snf-num">${s.num}</span>${s.label}
    </div>`;
  }).join('');
  return `<div class="section-nav-footer">
    <div class="snf-label">DiÄŸer BÃ¶lÃ¼mlere Git</div>
    <div class="snf-grid">${chips}</div>
  </div>`;
}

function loadSection(id) {
  document.querySelectorAll('.nav-item').forEach(n => n.classList.toggle('active', n.dataset.sec===id));
  document.querySelectorAll('.section').forEach(s => {
    const isActive = s.id === `sec-${id}`;
    s.classList.toggle('active', isActive);
    if (isActive) {
      // Remove existing footer if any, then append fresh one
      const old = s.querySelector('.section-nav-footer');
      if (old) old.remove();
      s.insertAdjacentHTML('beforeend', buildSectionNavFooter(id));
    }
  });
  stopTTS();
  window.scrollTo(0,0);
}

// ===================== TTS =====================
let ttsUtter = null;
function stopTTS() {
  window.speechSynthesis.cancel();
  document.getElementById('ttsStatus').textContent='BÃ¶lÃ¼m metnini sesli dinleyebilirsiniz';
}

document.getElementById('ttsPlay').addEventListener('click', () => {
  stopTTS();
  const active = document.querySelector('.section.active');
  if (!active) return;
  const text = active.innerText.replace(/\[[\d,]+\]/g,'').replace(/\s+/g,' ').trim();
  ttsUtter = new SpeechSynthesisUtterance(text);
  ttsUtter.lang = 'tr-TR';
  ttsUtter.rate = 0.9;
  ttsUtter.onend = () => { document.getElementById('ttsStatus').textContent='Okuma tamamlandÄ±'; };
  window.speechSynthesis.speak(ttsUtter);
  document.getElementById('ttsStatus').textContent='Sesli okuma devam ediyor...';
});

document.getElementById('ttsStop').addEventListener('click', stopTTS);

// ===================== QUIZ =====================
let qState = { idx:0, answers:[], answered:false };

function renderQuiz() {
  qState = { idx:0, answers:[], answered:false };
  showQuestion();
  renderQuizHistory();
}

function showQuestion() {
  const area = document.getElementById('quizArea');
  const q = QUIZ_QUESTIONS[qState.idx];
  const pct = Math.round((qState.idx / QUIZ_QUESTIONS.length) * 100);
  const keys = ['A','B','C','D'];

  area.innerHTML = `
    <div class="quiz-progress"><div class="quiz-progress-bar" style="width:${pct}%"></div></div>
    <div class="quiz-q-num">Soru ${qState.idx+1} / ${QUIZ_QUESTIONS.length} <span style="color:var(--text3);font-size:10px;margin-left:8px">â€” ÅÄ±kka tÄ±klayarak cevaplÄ±yÄ±n</span></div>
    <div class="quiz-question">${q.q}</div>
    <div class="quiz-options" id="qOpts">
      ${q.opts.map((o,i)=>`<div class="quiz-opt" data-idx="${i}"><span class="opt-key">${keys[i]}</span>${o}</div>`).join('')}
    </div>
    <div class="quiz-explain" id="qExp">${q.exp}</div>
    <div class="quiz-nav" id="qNav" style="display:none">
      <button class="quiz-btn primary" id="qNext">${qState.idx===QUIZ_QUESTIONS.length-1?'SonuÃ§larÄ± GÃ¶r âœ“':'Sonraki â†’'}</button>
    </div>
  `;

  document.getElementById('qOpts').addEventListener('click', e => {
    const opt = e.target.closest('.quiz-opt');
    if (!opt || qState.answered) return;
    qState.answered = true;
    qState.selected = parseInt(opt.dataset.idx);
    // Mark correct / wrong immediately
    document.querySelectorAll('.quiz-opt').forEach((o,i) => {
      o.style.pointerEvents = 'none';
      o.style.cursor = 'default';
      if (i === q.ans) {
        o.classList.add('correct');
        o.querySelector('.opt-key').textContent = 'âœ“';
      } else if (i === qState.selected) {
        o.classList.add('wrong');
        o.querySelector('.opt-key').textContent = 'âœ—';
      }
    });
    qState.answers.push(qState.selected === q.ans ? 1 : 0);
    document.getElementById('qExp').classList.add('show');
    document.getElementById('qNav').style.display = 'flex';
  });

  document.getElementById('qNext').addEventListener('click', async () => {
    if (qState.idx < QUIZ_QUESTIONS.length - 1) {
      qState.idx++;
      qState.answered = false;
      qState.selected = undefined;
      showQuestion();
    } else {
      await showResult();
    }
  });
}

async function showResult() {
  const score = qState.answers.reduce((a,b)=>a+b,0);
  const hist = await saveScore(score, QUIZ_QUESTIONS.length);
  const pct = Math.round((score/QUIZ_QUESTIONS.length)*100);
  let perf = pct>=90?'ğŸ† MÃ¼kemmel!':pct>=70?'âœ… Ä°yi iÅŸ!':pct>=50?'ğŸ“š Tekrar Ã¶nerilir':'ğŸ”„ Temel konularÄ± gÃ¶zden geÃ§ir';
  let col = pct>=90?'var(--success)':pct>=70?'var(--accent)':pct>=50?'var(--accent4)':'var(--danger)';

  document.getElementById('quizArea').innerHTML = `
    <div class="quiz-result">
      <div class="score" style="color:${col}">${score}<span style="font-size:32px;color:var(--text3)">/${QUIZ_QUESTIONS.length}</span></div>
      <div class="score-label">Toplam Puan</div>
      <div class="perf">${perf} â€” %${pct} baÅŸarÄ±</div>
      <div class="quiz-nav" style="justify-content:center;flex-wrap:wrap">
        <button class="quiz-btn primary" id="qRestart">ğŸ”„ Tekrar BaÅŸla</button>
        <button class="quiz-btn" id="qReview">ğŸ“‹ SorularÄ± GÃ¶zden GeÃ§ir</button>
        <button class="quiz-btn" id="qToHome" style="border-color:var(--accent);color:var(--accent)">ğŸ  ModÃ¼l Ana SayfasÄ±</button>
        <button class="quiz-btn" id="qLogout" style="border-color:var(--danger);color:var(--danger)">â Ã‡Ä±kÄ±ÅŸ Yap</button>
      </div>
    </div>
  `;
  document.getElementById('qRestart').addEventListener('click', () => { renderQuiz(); });
  document.getElementById('qReview').addEventListener('click', () => { qState.idx=0; qState.answered=false; qState.selected=undefined; showQuestion(); });
  document.getElementById('qToHome').addEventListener('click', () => { loadSection('home'); });
  document.getElementById('qLogout').addEventListener('click', () => { doLogout(); });
  renderQuizHistory(hist);
}

async function renderQuizHistory(hist) {
  if (!hist) hist = await loadHistory();
  const el = document.getElementById('quizHistory');
  if (!hist || !hist.length) { el.innerHTML=''; return; }
  el.innerHTML = `<div class="score-hist"><h4>ğŸ“Š GeÃ§miÅŸ Skorlar</h4>${hist.map(h=>`<div class="hist-item"><span>${h.date}</span><span class="hist-score">${h.score}/${h.total} (%${Math.round(h.score/h.total*100)})</span></div>`).join('')}</div>`;
}
</script>
</body>
</html>